Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-1290 inhibitor
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
The miR-1290 inhibitor is a synthetic, chemically modified oligonucleotide designed to silence the mature human microRNA hsa-miR-1290. It works by hybridizing with the mature miR-1290 sequence, thereby competitively preventing the microRNA from binding to its target mRNAs and inhibiting its biological function. In oncological research, miR-1290 has been identified as an oncomiR that promotes cell proliferation, epithelial-mesenchymal transition (EMT), and resistance to chemotherapy (such as 5-fluorouracil) by downregulating tumor suppressors like hMSH2. The inhibitor is used in preclinical studies to investigate its potential in treating various cancers, including multiple myeloma, colorectal cancer, and ovarian cancer. It is currently available as a research-use-only (RUO) reagent from various commercial suppliers.
- Brand names
- mirVana miRNA Inhibitor
- Other names
- hsa-miR-1290 inhibitorhsa-miR1290 inhibitorhsa-miR 1290 inhibitoranti-miR-1290anti-miR1290anti-miR 1290miR-1290 antagomirmiR1290 antagomirmiR 1290 antagomir
02
Targets
miR-1290 (Homo sapiens microRNA 1290)
Beyond the preview
Go deeper on miR-1290 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-1290 inhibitor.